{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:05:00Z","timestamp":1785229500513,"version":"3.55.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>Helicobacter pylori (H. pylori)<\/jats:italic>\n                    is a globally prevalent bacterium that causes chronic infection and, while often asymptomatic, is a major cause of gastritis, peptic ulcer disease, and a risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Infection triggers robust innate and adaptive immune responses in the gastric mucosa, including immune cell recruitment and pro-inflammatory cytokine production; however, the bacterium frequently persists by evading host immunity through mechanisms such as CagA-mediated epithelial damage and modulation of heat shock proteins. This review examines the interplay between mucosal immunity and\n                    <jats:italic>H. pylori<\/jats:italic>\n                    , with a particular focus on the unique functional roles of mucosa-associated invariant T (MAIT) cells in orchestrating host defense. We also explore therapeutic strategies that leverage mucosal immunity to combat\n                    <jats:italic>H. pylori<\/jats:italic>\n                    , including immune-based interventions to eradicate infection and approaches targeting\n                    <jats:italic>H. pylori<\/jats:italic>\n                    -associated diseases, such as gastric cancer, autoimmune disorders, and peptic ulcer disease.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1727910","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:47:21Z","timestamp":1785228441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the gastric frontier of mucosal immunity against Helicobacter pylori"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Department of Bioengineering, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Microbiome Vaccine Program, Goodman-Luskin Microbiome Center, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Department of Bioengineering, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Department of Bioengineering, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Department of Bioengineering, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Microbiome Vaccine Program, Goodman-Luskin Microbiome Center, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Department of Bioengineering, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Microbiome Vaccine Program, Goodman-Luskin Microbiome Center, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Molecular Biology Institute, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Parker Institute for Cancer Immunotherapy, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/children9091359","article-title":"Worldwide prevalence and risk factors of Helicobacter pylori infection in children","volume":"9","author":"Borka Balas","year":"2022","journal-title":"Child (Basel Switzerland)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and gastric cancer: factors that modulate disease risk","volume":"23","author":"Wroblewski","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11051312","article-title":"Helicobacter pylori and its role in gastric cancer","volume":"11","author":"Reyes","year":"2023","journal-title":"Microorganisms"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.083","article-title":"Helicobacter pylori and MALT lymphoma","volume":"128","author":"Farinha","year":"2005","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-016-0068-1","article-title":"Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management","volume":"4","author":"Hu","year":"2016","journal-title":"biomark Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X08094880","article-title":"Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone","volume":"1","author":"Lee","year":"2008","journal-title":"Therap Adv Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i25.3811","article-title":"Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users","volume":"11","author":"Papatheodoridis","year":"2005","journal-title":"World J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012877","article-title":"Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use","volume":"346","author":"Lai","year":"2002","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i19.5583","article-title":"Immune responses to Helicobacter pylori infection","volume":"20","author":"Moyat","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12964-024-01627-5","article-title":"Helicobacter pylori disrupts gastric mucosal homeostasis by stimulating macrophages to secrete CCL3","volume":"22","author":"Wei","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1186\/s12885-025-14436-x","article-title":"Impact of helicobacter pylori infection on the efficacy of ICIs in gastric cancer","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canlet.2013.08.016","article-title":"Helicobacter pylori-induced gastric inflammation and gastric cancer","volume":"345","author":"Wang","year":"2014","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923477","article-title":"Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70015","article-title":"Innate immunity in Helicobacter pylori infection and gastric oncogenesis","volume":"30","author":"Zhang","year":"2025","journal-title":"Helicobacter"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1342913","article-title":"Strategies of Helicobacter pylori in evading host innate and adaptive immunity: insights and prospects for therapeutic targeting","volume":"14","author":"Fan","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-9-25","article-title":"H. pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection","volume":"9","author":"M\u00fcller","year":"2011","journal-title":"Cell Commun Signal"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9219-x","article-title":"The role of lipopolysaccharide\/toll-like receptor 4 signaling in chronic liver diseases","volume":"4","author":"Soares","year":"2010","journal-title":"Hepatol Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585146","article-title":"Lipopolysaccharide recognition in the crossroads of TLR4 and Caspase-4\/11 mediated inflammatory pathways","volume":"11","author":"Zamyatina","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010033","article-title":"Bacterial lymphatic metastasis in infection and immunity","volume":"11","author":"Siggins","year":"2021","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1053\/j.gastro.2007.05.008","article-title":"Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies","volume":"133","author":"Wilson","year":"2007","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i36.12753","article-title":"Immune evasion strategies used by Helicobacter pylori","volume":"20","author":"Lina","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2025.101470","article-title":"Decoding the ability of Helicobacter pylori to evade immune recognition and cause disease","volume":"19","author":"Sirit","year":"2025","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12929-025-01125-x","article-title":"Biological functions and therapeutic applications of human mucosal-associated invariant T cells","volume":"32","author":"Fang","year":"2025","journal-title":"J BioMed Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.11.019","article-title":"Mucosal-associated invariant T cells for cancer immunotherapy","volume":"31","author":"Li","year":"2022","journal-title":"Mol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2025.03.011","article-title":"The microbiota shapes the life trajectory of mucosal-associated invariant T cells","volume":"33","author":"Li","year":"2025","journal-title":"Trends Microbiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i36.12767","article-title":"Effect of Helicobacter pylori on gastric epithelial cells","volume":"20","author":"Alzahrani","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3016","article-title":"Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori","volume":"11","author":"Salama","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-77","article-title":"The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis","volume":"11","author":"Posselt","year":"2013","journal-title":"Cell Commun Signal"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1290833","article-title":"Helicobacter pylori induces a novel form of innate immune memory via accumulation of NF-\u043aB proteins","volume":"14","author":"Frauenlob","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070725","article-title":"Unraveling Helicobacter pylori: insights into pathogenesis, immune evasion, and progress toward effective vaccination","volume":"13","author":"Elbehiry","year":"2025","journal-title":"Vaccines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1593727","article-title":"The immunoregulatory role of helper T cells in Helicobacter pylori infection","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00302","article-title":"Role of innate T cells in anti-bacterial immunity","volume":"6","author":"Gao","year":"2015","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0191-y","article-title":"Mucosal-associated invariant T cells and disease","volume":"19","author":"Toubal","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13058-018-1036-5","article-title":"Mucosal associated invariant T cells from human breast ducts mediate a Th17-skewed response to bacterially exposed breast carcinoma cells","volume":"20","author":"Zumwalde","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353789","article-title":"Human MAIT and CD8\u03b1\u03b1 cells develop from a pool of type-17 precommitted CD8+ T cells","volume":"119","author":"Walker","year":"2012","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12277","article-title":"Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases","volume":"176","author":"Serriari","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1038\/s41467-024-53657-9","article-title":"Protective effect of TCR-mediated MAIT cell activation during experimental autoimmune encephalomyelitis","volume":"15","author":"Walkenhorst","year":"2024","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-445429","article-title":"Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection","volume":"121","author":"Leeansyah","year":"2013","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41467-021-21928-4","article-title":"Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy","volume":"12","author":"De Biasi","year":"2021","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0072-x","article-title":"Tuning of human MAIT cell activation by commensal bacteria species and MR1-dependent T-cell presentation","volume":"11","author":"Tastan","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.017","article-title":"Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1","volume":"64","author":"Jeffery","year":"2016","journal-title":"J Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432651","article-title":"Insights into the tissue repair features of MAIT cells","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.immuni.2022.12.004","article-title":"Role of MR1-driven signals and amphiregulin on the recruitment and repair function of MAIT cells during skin wound healing","volume":"56","author":"du Halgouet","year":"2023","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.09.009","article-title":"MAIT cell development and functions: the microbial connection","volume":"53","author":"Legoux","year":"2020","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01014","article-title":"MAIT cell activation and functions","volume":"11","author":"Hinks","year":"2020","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00466","article-title":"Mucosal-associated invariant T cells in the human gastric mucosa and blood: role in Helicobacter pylori infection","volume":"6","author":"Booth","year":"2015","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626017","article-title":"OX40L\/OX40 signal promotes IL-9 production by mucosal MAIT cells during Helicobacter pylori infection","volume":"12","author":"Ming","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0465-3","article-title":"Molecular mechanisms of lineage decisions in metabolite-specific T cells","volume":"20","author":"Legoux","year":"2019","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7372","DOI":"10.1038\/s41467-023-43269-0","article-title":"Mucosal-associated invariant T cells contribute to suppression of inflammatory myeloid cells in immune-mediated kidney disease","volume":"14","author":"Gnirck","year":"2023","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3298","article-title":"The burgeoning family of unconventional T cells","volume":"16","author":"Godfrey","year":"2015","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-1-0716-0207-2_7","article-title":"Human MAIT cell activation in vitro","volume":"2098","author":"Hagel","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw2719","article-title":"Microbial metabolites control the thymic development of mucosal-associated invariant T cells","volume":"366","author":"Legoux","year":"2019","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0925","article-title":"Activating mucosal-associated invariant T cells induces a broad antitumor response","volume":"9","author":"Ruf","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0569","article-title":"MAIT cells promote tumor initiation, growth, and metastases via tumor MR1","volume":"10","author":"Yan","year":"2020","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999549","article-title":"Target tumor microenvironment by innate T cells","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"B61","first-page":"1","volume-title":"The Role of Innate T Cells in Cancer BT - Handbook of Cancer and Immunology","author":"Chen","year":"2022"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112749","article-title":"Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100856","article-title":"Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy","volume":"209","author":"Dogan","year":"2022","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2021.07.003","article-title":"Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy","volume":"108","author":"Bohineust","year":"2021","journal-title":"Bull Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044084","article-title":"Graft-versus-host disease modulation by innate T cells","volume":"24","author":"Fang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123497","article-title":"Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12185-018-2442-2","article-title":"Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation","volume":"108","author":"Kawaguchi","year":"2018","journal-title":"Int J Hematol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood-2019-127722","article-title":"The low number of mucosal-associated invariant T cells in the graft was associated with occurrence of gut graft-versus-host disease","volume":"134","author":"Mengge","year":"2019","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"100677","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med (New York NY)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: Treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-017-0157-8","article-title":"Best practice recommendations for diagnosis and management of Helicobacter pylori-synthesizing the guidelines","volume":"15","author":"Bjorkman","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/hel.12287","article-title":"Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: Effect of resistance, duration, and CYP2C19 genotype","volume":"21","author":"Graham","year":"2016","journal-title":"Helicobacter"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13103","article-title":"Global primary antibiotic resistance rate of Helicobacter pylori in recent 10\u2009years: A systematic review and meta-analysis","volume":"29","author":"Yu","year":"2024","journal-title":"Helicobacter"},{"key":"B75","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21\u2009533 patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12091427","article-title":"Analysis of clinical phenotypes through machine learning of first-line H. pylori treatment in Europe during the period 2013-2022: Data from the European registry on H. pylori management (Hp-EuReg)","volume":"12","author":"Nyssen","year":"2023","journal-title":"Antibiot (Basel Switzerland)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: Treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2024.1410816","article-title":"Molecular tools of antibiotic resistance for Helicobacter pylori: An overview in Latin America","volume":"3","author":"Contreras","year":"2024","journal-title":"Front Gastroenterol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cell.2018.08.047","article-title":"Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT","volume":"174","author":"Suez","year":"2018","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"10069","DOI":"10.1038\/s41598-024-59399-4","article-title":"The effects of probiotics supplementation on Helicobacter pylori standard treatment: An umbrella review of systematic reviews with meta-analyses","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2024.11.016","article-title":"Efficacy of probiotics regimens for Helicobacter pylori eradication: A systematic review, pairwise, and network meta-analysis of randomized controlled trials","volume":"65","author":"Tanashat","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2021.20923","article-title":"Efficacy of lactoferrin with standard triple therapy or sequential therapy for Helicobacter pylori eradication: A randomized controlled trial","volume":"32","author":"Hablass","year":"2021","journal-title":"Turkish J Gastroenterol Off J Turkish Soc Gastroenterol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12040599","article-title":"Antimicrobial effects of lactoferrin against Helicobacter pylori infection","volume":"12","author":"Imoto","year":"2023","journal-title":"Pathog (Basel Switzerland)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.566730","article-title":"Vitamin D3 inhibits Helicobacter pylori infection by activating the VitD3\/VDR-CAMP pathway in mice","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1033201","article-title":"Vitamin D(3) eradicates Helicobacter pylori by inducing VDR-CAMP signaling","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Microbiol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12769","article-title":"Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis","volume":"29","author":"Nishizawa","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091498","article-title":"Efficiency of the inclusion of rebamipide in the eradication therapy for Helicobacter pylori infection: Meta-analysis of randomized controlled studies","volume":"8","author":"Andreev","year":"2019","journal-title":"J Clin Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050526","article-title":"Helicobacter pylori vaccine: Mechanism of pathogenesis, immune evasion and analysis of vaccine types","volume":"13","author":"Gong","year":"2025","journal-title":"Vaccines"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"Lancet (London England)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v7.i3.412","article-title":"Chinese Helicobacter pylori vaccine: Solution for an old challenge","volume":"7","author":"Talebi Bezmin Abadi","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2024.19","article-title":"Developing a potent vaccine against Helicobacter pylori: Critical considerations and challenges","volume":"27","author":"Hasanzadeh Haghighi","year":"2024","journal-title":"Expert Rev Mol Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2425773","article-title":"Adjuvants for Helicobacter pylori vaccines: Outer membrane vesicles provide an alternative strategy","volume":"15","author":"Zhang","year":"2024","journal-title":"Virulence"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944139","article-title":"HP-NAP of Helicobacter pylori: The power of the immunomodulation","volume":"13","author":"Codolo","year":"2022","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2009.10.032","article-title":"Nanosystem drug targeting: Facing up to complex realities","volume":"141","author":"Ruenraroengsak","year":"2010","journal-title":"J Control Release Off J Control Release Soc"},{"key":"B99","doi-asserted-by":"publisher","first-page":"17910","DOI":"10.1038\/s41598-024-68947-x","article-title":"Immunoinformatics design and synthesis of a multi-epitope vaccine against Helicobacter pylori based on lipid nanoparticles","volume":"14","author":"Jebali","year":"2024","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s12602-024-10360-x","article-title":"Oral live-carrier vaccine of recombinant Lactococcus lactis inducing prophylactic protective immunity against Helicobacter pylori infection","volume":"17","author":"Ni","year":"2024","journal-title":"Probiotics Antimicrob Proteins"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13128","article-title":"Candidate antigens and the development of Helicobacter pylori vaccines","volume":"29","author":"Zhang","year":"2024","journal-title":"Helicobacter"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.036","article-title":"Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection","volume":"38","author":"Liu","year":"2020","journal-title":"Vaccine"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101183","article-title":"Vaccination against Helicobacter pylori - an approach for cancer prevention","volume":"92","author":"Friedrich","year":"2023","journal-title":"Mol Aspects Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70063-6","article-title":"Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults","volume":"116","author":"Michetti","year":"1999","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.001","article-title":"Status of vaccine research and development for Helicobacter pylori","volume":"37","author":"Sutton","year":"2019","journal-title":"Vaccine"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"B107","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ajg.2017.154","article-title":"ACG and CAG clinical guideline: Management of dyspepsia","volume":"112","author":"Moayyedi","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093258","article-title":"Standard bismuth quadruple therapy versus concomitant therapy for the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zagari","year":"2023","journal-title":"J Clin Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/antibiotics13040348","article-title":"Concomitant and bismuth quadruple therapy for Helicobacter pylori eradication in southern Italy: Preliminary data from a randomized clinical trial","volume":"13","author":"Losurdo","year":"2024","journal-title":"Antibiot (Basel Switzerland)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.1983-1988.2004","article-title":"The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation","volume":"48","author":"Bland","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13111004","article-title":"In vitro susceptibility and synergistic effect of bismuth against Helicobacter pylori","volume":"13","author":"Woo","year":"2024","journal-title":"Antibiot (Basel Switzerland)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: a review in Helicobacter pylori infection","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i27.3304","article-title":"Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study","volume":"30","author":"Huang","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251354868","article-title":"Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for Helicobacter pylori treatment: a randomized clinical trial","volume":"18","author":"Zhang","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S325056","article-title":"Development and validation of multiplex quantitative PCR assay for detection of Helicobacter pylori and mutations conferring resistance to clarithromycin and levofloxacin in gastric biopsy","volume":"14","author":"Binmaeil","year":"2021","journal-title":"Infect Drug Resist"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.913436","article-title":"Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: A systematic review and meta-analysis","volume":"13","author":"Nyssen","year":"2022","journal-title":"Front Microbiol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.844915","article-title":"Susceptibility-guided therapy vs. bismuth-containing quadruple therapy as the first-line treatment for Helicobacter pylori infection: A systematic review and meta-analysis","volume":"9","author":"Ouyang","year":"2022","journal-title":"Front Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ueg2.12473","article-title":"The use of non-invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance","volume":"11","author":"Mommersteeg","year":"2023","journal-title":"United Eur Gastroenterol J"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012357.pub2","article-title":"N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication","volume":"2","author":"Fontes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101832","article-title":"The efficacy of adjuvant N acetyl cysteine for the eradication of H pylori infections: A systematic review and meta-analysis of randomized clinical trials","volume":"46","author":"Biswas","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113236","article-title":"Stomach encyclopedia: Combined single-cell and spatial transcriptomics reveal cell diversity and homeostatic regulation of human stomach","volume":"42","author":"Tsubosaka","year":"2023","journal-title":"Cell Rep"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.10.012","article-title":"Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori","volume":"74","author":"Li","year":"2025","journal-title":"J Adv Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1038\/s41467-025-59339-4","article-title":"Single-cell RNA sequencing dissects the immunosuppressive signatures in Helicobacter pylori-infected human gastric ecosystem","volume":"16","author":"Hu","year":"2025","journal-title":"Nat Commun"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161042","article-title":"Metagenomic and single-cell RNA-Seq survey of the Helicobacter pylori-infected stomach in asymptomatic individuals","volume":"8","author":"Sorini","year":"2023","journal-title":"JCI Insight"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41467-025-57131-y","article-title":"Accessible homeostatic gastric organoids reveal secondary cell type-specific host-pathogen interactions in Helicobacter pylori infections","volume":"16","author":"Hofer","year":"2025","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12891","article-title":"Gastric organoids: Advancing the study of H. pylori pathogenesis and inflammation","volume":"27","author":"Idowu","year":"2022","journal-title":"Helicobacter"},{"key":"B127","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcmgh.2021.09.005","article-title":"Gastric organoids: Progress and remaining challenges","volume":"13","author":"Pang","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s42003-024-05912-4","article-title":"Delivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activation","volume":"7","author":"Kulicke","year":"2024","journal-title":"Commun Biol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41698-025-00816-w","article-title":"A spatial transcriptomic signature of 26 genes resolved at single-cell resolution characterizes high-risk gastric cancer precursors","volume":"9","author":"Huang","year":"2025","journal-title":"NPJ Precis Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1727910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:47:23Z","timestamp":1785228443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1727910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":129,"alternative-id":["10.3389\/fimmu.2026.1727910"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1727910","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1727910"}}